August 2012
-
Spray characterization specialist Proveris Scientific has announced that it is now offering contract testing services for OINDP regulatory submissions, release testing and stability studies, as well as for development projects. The company received ISO 9001:2015… Read more . . .
-
Pulmotect said that it plans to initiate two Phase 2 trials of its PUL-042 immunostimulant inhalation solution for the prevention and treatment of COVID-19 within a week after getting the go-ahead from the FDA. In… Read more . . .
-
The FDA has approved an IND for a Phase 2 study of GeneOne Life Science’s GLS-1200 nasal spray for the prevention of COVID-19, the company said. According to GeneOne, GLS-1200 stimulates nasal production of nitric… Read more . . .
-
Impel NeuroPharma has announced the resignation of Jon Congleton as President and CEO; Adrian Adams, who was appointed as Impel’s Chairman of the Board of Directors in January 2020, will now add the CEO role. Adams has… Read more . . .
-
DPI developer Iconovo has announced that Amneal will take over development of a generic version of Symbicort based on Iconovo’s multi-dose ICOres device. Iconovo and Amneal initially signed a licensing and development deal in 2016.… Read more . . .
-
The American Academy of Allergy, Asthma & Immunology (AAAAI) has published results of three Phase 1 studies of ARS Pharmaceuticals’ ARS-1 (Neffy) intranasal epinephrine that had been scheduled for presentation at the AAAAI annual meeting.… Read more . . .
-
Hovione has announced the appointment of former Evonik executive Jean-Luc Herbeaux as the company’s new Chief Operating Officer. Herbeaux was most recently Senior VP and General Manager of Evonik’s Health Care Business Line. He will… Read more . . .
-
The Finnish Medicines Agency has granted GMP certification to nanonization specialist Nanoform Finland, the company said. In December 2019, Nanoform announced that it had applied for the certification. The company’s CESS (controlled expansion of supercritical… Read more . . .
-
Alnylam Pharmaceuticals and Vir Biotechnology have announced that they intend to meet with the FDA soon regarding an IND for VIR-2703 (ALN-COV), an inhaled siRNA in development for prevention and/or treatment of COVID-19. The companies… Read more . . .
-
3M announced that it has completed the sale of “substantially all” of 3M Drug Delivery Systems to Altaris Capital Partners, and the new company is now known as Kindeva Drug Delivery. The initial announcement of… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.